CTLA4 and neoplasm: Priming is a crucial step in boosting anti-tumor immune responses with treatments such as anti-CTLA-4 antibodies (41) and is a known contributor to the increased sensitivity of the CT26 tumor model to immunotherapy, as it is a self-priming model (42).